Header

UZH-Logo

Maintenance Infos

International classification of functioning, disability and health core set construction in systemic sclerosis and other rheumatic diseases: a EUSTAR initiative


Saketkoo, Lesley Ann; Escorpizo, Reuben; Keen, Kevin J; Fligelstone, Kim; Distler, Oliver (2012). International classification of functioning, disability and health core set construction in systemic sclerosis and other rheumatic diseases: a EUSTAR initiative. Rheumatology, 51(12):2170-2176.

Abstract

OBJECTIVES: To outline rationale and potential strategies for rheumatology experts to be able to develop disease-specific Core Sets under the framework of the International Classification of Functioning, Disability and Health (ICF). ICF is a universal framework introduced by the World Health Organization (WHO) to describe and quantify the impact and burden on functioning of health conditions associated with impairment/disability.
METHODS: A combined effort of the EULAR Scleroderma Clinical Trial and Research and the ICF Research Branch was initiated to develop an ICF language for scleroderma. From our Medline literature review, using the abbreviation and spelled out version of ICF, we assembled approaches and methodological reasoning for steps of core set development.
RESULTS: The ICF can be used for patient care and policy-making, as well as the provision of resources, services and funding. The ICF is used on institutional, regional, national and global levels. Several diseases now have ICF Core Sets. Patients with complex rheumatologic diseases will benefit from a disease-specific ICF Core Set and should be included in all stages of development. ICF Core Set development for rheumatic diseases can be conducted from a number of feasible strategies.
CONCLUSION: This overview should help to clarify useful processes leading to development of an ICF Core Set, and also provide a platform for expert groups considering such an endeavour.

Abstract

OBJECTIVES: To outline rationale and potential strategies for rheumatology experts to be able to develop disease-specific Core Sets under the framework of the International Classification of Functioning, Disability and Health (ICF). ICF is a universal framework introduced by the World Health Organization (WHO) to describe and quantify the impact and burden on functioning of health conditions associated with impairment/disability.
METHODS: A combined effort of the EULAR Scleroderma Clinical Trial and Research and the ICF Research Branch was initiated to develop an ICF language for scleroderma. From our Medline literature review, using the abbreviation and spelled out version of ICF, we assembled approaches and methodological reasoning for steps of core set development.
RESULTS: The ICF can be used for patient care and policy-making, as well as the provision of resources, services and funding. The ICF is used on institutional, regional, national and global levels. Several diseases now have ICF Core Sets. Patients with complex rheumatologic diseases will benefit from a disease-specific ICF Core Set and should be included in all stages of development. ICF Core Set development for rheumatic diseases can be conducted from a number of feasible strategies.
CONCLUSION: This overview should help to clarify useful processes leading to development of an ICF Core Set, and also provide a platform for expert groups considering such an endeavour.

Statistics

Citations

Dimensions.ai Metrics
16 citations in Web of Science®
20 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

28 downloads since deposited on 14 Feb 2013
4 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Rheumatology Clinic and Institute of Physical Medicine
Dewey Decimal Classification:610 Medicine & health
Scopus Subject Areas:Health Sciences > Rheumatology
Health Sciences > Pharmacology (medical)
Language:English
Date:2012
Deposited On:14 Feb 2013 16:49
Last Modified:23 Jan 2022 23:48
Publisher:Oxford University Press
ISSN:1462-0324
OA Status:Hybrid
Publisher DOI:https://doi.org/10.1093/rheumatology/kes185
PubMed ID:22919048
  • Content: Published Version
  • Language: English
  • Description: Nationallizenz 142-005